Invernova S.A. (SNSE:INVERNOVA)

Elevation Oncology Balance Sheet

Financials in millions CLP. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	1,353	945.31	2,326	2,771	2,614	2,190
Cash & Short-Term Investments	1,353	945.31	2,326	2,771	2,614	2,190
Cash Growth	-41.81%	-59.37%	-16.05%	6.00%	19.37%	8.71%
Accounts Receivable	4.04	4.04	4.15	2.6	1.56	1.61
Other Receivables	-	-	1.96	-	-	-
Receivables	4.04	4.04	6.11	2.6	1.56	1.61
Total Current Assets	1,357	949.35	2,332	2,774	2,616	2,192
Long-Term Investments	6,199	6,294	5,588	5,100	4,391	3,684
Total Assets	8,085	8,186	8,315	8,620	8,346	7,888
Accounts Payable	-	-	-	-	-	0.7
Accrued Expenses	17.31	12.98	11.08	9.57	9.52	9.03
Other Current Liabilities	277.09	277.09	258.29	342.49	242.97	79.94
Total Current Liabilities	294.4	290.06	269.37	352.06	252.49	89.67
Long-Term Unearned Revenue	1,101	1,107	1,266	1,343	1,399	1,490
Total Liabilities	1,396	1,397	1,536	1,695	1,652	1,580
Common Stock	2,662	2,662	2,662	2,662	2,662	2,662
Retained Earnings	3,068	3,167	3,158	3,303	3,073	2,687
Comprehensive Income & Other	958.98	958.98	958.98	958.98	958.98	958.98
Shareholders' Equity	6,689	6,788	6,779	6,925	6,694	6,308
Total Liabilities & Equity	8,085	8,186	8,315	8,620	8,346	7,888
Net Cash (Debt)	1,353	945.31	2,326	2,771	2,614	2,190
Net Cash Growth	-41.81%	-59.37%	-16.05%	6.00%	19.37%	8.71%
Net Cash Per Share	1.89	1.32	3.25	3.88	3.66	3.06
Filing Date Shares Outstanding	714.88	714.88	714.88	714.88	714.88	714.88
Total Common Shares Outstanding	714.88	714.88	714.88	714.88	714.88	714.88
Working Capital	1,062	659.29	2,063	2,422	2,363	2,102
Book Value Per Share	9.36	9.50	9.48	9.69	9.36	8.82
Tangible Book Value	6,689	6,788	6,779	6,925	6,694	6,308
Tangible Book Value Per Share	9.36	9.50	9.48	9.69	9.36	8.82

Source: S&P Global Market Intelligence. Standard template. Financial Sources.